Gilboa Mayan, Koren Gideon, Katz Racheli, Melzer-Cohen Cheli, Shalev Varda, Grossman Ehud
Internal Medicine D, The Chaim Sheba Medical Center, Tel-Hashomer.
Sackler Faculty of Medicine, Tel Aviv University.
Medicine (Baltimore). 2019 Feb;98(5):e14334. doi: 10.1097/MD.0000000000014334.
The aim of the study was to define whether anxiety itself or only the treatment with anxiolytic medication is risk factor for hyponatremia and overhydration.A case-control study of patients with a diagnosis of anxiety who received a selective serotonin reuptake inhibitor (SSRI). Serum sodium, urea to creatinine ratio, and odds ratio (OR) of hyponatremia and overhydration before initiation of treatment were compared to those of a control group of participants. Laboratory tests were also examined for changes following treatment with an SSRI. All blood tests were conducted from January 1, 2001 until December 31, 2017. Subjects were selected from a large electronic database, insuring 2 million Israelis. A total of 7211 patients with a diagnosis of anxiety who have received a prescription for an SSRI were identified; 3634 were excluded mostly due to other conditions that could cause hyponatremia, and 3520 participants were included in the case group. The control group consisted of 6985 age and gender matched participants who did not have a diagnosis of anxiety or any other exclusion criteria.Mean serum sodium levels were elevated in cases before the initiation of SSRIs; sodium: case 139.3 (137.3-141.3), control 139.2 (137.06-141.26) mmol/L (P = .01). The OR of hyponatremia was 0.89 for the case group (P = .004). Treatment with SSRIs decreased mean serum sodium (139.3-139.1 mmol/L; P = .0001) and increased by 50% the rate of hyponatremia (2.6-3.9% P = .024).It is the use of SSRIs and not anxiety itself that causes hyponatremia among anxious patients.
该研究的目的是确定焦虑本身还是仅使用抗焦虑药物治疗是低钠血症和水过多的危险因素。对诊断为焦虑症并接受选择性5-羟色胺再摄取抑制剂(SSRI)治疗的患者进行病例对照研究。将治疗开始前低钠血症和水过多的血清钠、尿素肌酐比值及比值比(OR)与对照组参与者进行比较。还检查了SSRI治疗后实验室检查的变化。所有血液检查均在2001年1月1日至2017年12月31日期间进行。研究对象从一个涵盖200万以色列人的大型电子数据库中选取。共识别出7211例诊断为焦虑症并接受SSRI处方的患者;3634例因其他可能导致低钠血症的疾病被排除,3520例参与者被纳入病例组。对照组由6985例年龄和性别匹配、未诊断为焦虑症或无任何其他排除标准的参与者组成。病例组在开始使用SSRI前平均血清钠水平升高;钠:病例组139.3(137.3 - 141.3),对照组139.2(137.06 - 141.26)mmol/L(P = 0.01)。病例组低钠血症的OR为0.89(P = 0.004)。SSRI治疗使平均血清钠降低(139.3 - 139.1 mmol/L;P = 0.0001),并使低钠血症发生率增加50%(2.6 - 3.9%,P = 0.024)。是使用SSRI而非焦虑本身导致焦虑症患者出现低钠血症。